Quinocarmycin Analog DX-52-1 Inhibits Cell Migration and Targets Radixin, Disrupting Interactions of Radixin with Actin and CD44

Chemistry and Biology

Volumn 13, Issue 9, 2006, Pages 973-983

  Kahsai, Alem W ^a   Zhu, Shoutian ^b   Wardrop, Duncan J ^b   Lane, William S ^c   Fenteany, Gabriel ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CYTOSKELETON PROTEIN; DX 52-1; HERMES ANTIGEN; ISOQUINOLINE DERIVATIVE; MEMBRANE PROTEIN; QUINOCARMYCIN; RADIXIN;

ANIMAL; ARTICLE; BIOTINYLATION; CELL LINE; CELL MOTION; CHEMISTRY; CYTOLOGY; DOG; DRUG EFFECT; EPITHELIUM CELL; GENETIC TRANSFECTION; GENETICS; HUMAN; IC 50; INSECT; METABOLISM; MOUSE; PROTEIN BINDING; RNA INTERFERENCE; SYNTHESIS;

ACTINS; ANIMALS; ANTIGENS, CD44; BIOTINYLATION; CELL LINE; CELL MOVEMENT; CYTOSKELETAL PROTEINS; DOGS; EPITHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; INSECTS; ISOQUINOLINES; MEMBRANE PROTEINS; MICE; PROTEIN BINDING; RNA INTERFERENCE; TRANSFECTION;

EID: 33748558778     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2006.07.011     Document Type: Article

References (85)

1. Small J.V., Stradel T., Vignal E., and Rottner K. The lamellipodium: where motility begins. Trends Cell Biol. 12 (2002) 112-120
2. Welch M.D., and Mullins R.D. Cellular control of actin nucleation. Annu. Rev. Cell Dev. Biol. 18 (2002) 247-288
3. Carlier M.F., Clainche C.L., Wiesner S., and Pantaloni D. Actin-based motility: from molecules to movement. Bioessays 25 (2003) 336-345
4. Fenteany G., and Zhu S. Small-molecule inhibitors of actin dynamics and cell motility. Curr. Top. Med. Chem. 3 (2003) 593-616
5. Pollard T.D., and Borisy G.G. Cellular motility driven by assembly and disassembly of actin filaments. Cell 112 (2003) 453-465
6. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Parsons J.T., and Horwitz A.R. Cell migration: integrating signals from front to back. Science 302 (2003) 1704-1709
7. Lambrechts A., Van Troys M., and Ampe C. The actin cytoskeleton in normal and pathological cell motility. Int. J. Biochem. Cell Biol. 36 (2004) 1890-1909
8. Rafelski S.M., and Theriot J.A. Crawling toward a unified model of cell motility: spatial and temporal regulation of actin dynamics. Annu. Rev. Biochem. 73 (2004) 209-239
9. Raftopoulou M., and Hall A. Cell migration: Rho GTPases lead the way. Dev. Biol. 265 (2004) 23-32
10. Revenu C., Athman R., Robine S., and Louvard D. The co-workers of actin filaments: from cell structures to signals. Nat. Rev. Mol. Cell Biol. 5 (2004) 635-646
11. Disanza A., Steffen A., Hertzog M., Frittoli E., Rottner K., and Scita G. Actin polymerization machinery: the finish line of signaling networks, the starting point of cellular movement. Cell. Mol. Life Sci. 62 (2005) 955-970
12. Plastino J., and Sykes C. The actin slingshot. Curr. Opin. Cell Biol. 17 (2005) 62-66
13. Li S., Guan J.L., and Chien S. Biochemistry and biomechanics of cell motility. Annu. Rev. Biomed. Eng. 7 (2005) 105-150
14. Webb D.J., Zhang H., and Horwitz A.F. Cell migration: an overview. Methods Mol. Biol. 294 (2005) 3-11
15. Mc Henry K.T., Ankala S.V., Ghosh A.K., and Fenteany G. A non-antibacterial oxazolidinone derivative that inhibits epithelial cell sheet migration. ChemBioChem 3 (2002) 1105-1111
16. Fenteany G., Janmey P.A., and Stossel T.P. Signaling pathways and cell mechanics involved in wound closure by epithelial cell sheets. Curr. Biol. 10 (2000) 831-838
17. Farooqui R., and Fenteany G. Multiple rows of cells behind an epithelial wound edge extend cryptic lamellipodia to collectively drive cell-sheet movement. J. Cell Sci. 118 (2005) 51-63
18. Burridge K., and Wennerberg K. Rho and Rac take center stage. Cell 116 (2004) 167-179
19. Wennerberg K., and Der C.J. Rho-family GTPases: it's not only Rac and Rho (and I like it). J. Cell Sci. 117 (2004) 1301-1312
20. Jaffe A.B., and Hall A. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 21 (2005) 247-269
21. Titus B., Schwartz M.A., and Theodorescu D. Rho proteins in cell migration and metastasis. Crit. Rev. Eukaryot. Gene Expr. 15 (2005) 103-114
22. Farooqui R., Zhu S., and Fenteany G. Glycogen synthase kinase-3 acts upstream of ADP-ribosylation factor 6 and Rac1 to regulate epithelial cell migration. Exp. Cell Res. 312 (2006) 1514-1525
23. Santy L.C., and Casanova J.E. Activation of ARF6 by ARNO stimulates epithelial cell migration through downstream activation of both Rac1 and phospholipase D. J. Cell Biol. 154 (2001) 599-610
24. Altan Z.M., and Fenteany G. c-Jun N-terminal kinase regulates lamellipodial protrusion and cell sheet migration during epithelial wound closure by a gene expression-independent mechanism. Biochem. Biophys. Res. Commun. 322 (2004) 56-67
25. Zhu S., Mc Henry K.T., Lane W.S., and Fenteany G. A chemical inhibitor reveals the role of Raf kinase inhibitor protein in cell migration. Chem. Biol. 12 (2005) 981-991
26. Tomita F., Takahashi K., and Shimizu K. DC-52, a novel antitumor antibiotic. 1. Taxonomy, fermentation and biological activity. J. Antibiot. (Tokyo) 36 (1983) 463-467
27. Tomita F., Takahashi K., and Tamaoki T. Quinocarcin, a novel antitumor antibiotic. 3. Mode of action. J. Antibiot. (Tokyo) 37 (1984) 1268-1272
28. Chiang C.D., Kanzawa F., Matsushima Y., Nakano H., Nakagawa K., Takahashi H., Terada M., Morinaga S., Tsuchiya R., Sasaki Y., et al. Antitumor activity of quinocarmycin against carcinoma of the lung in human tumor clonogenic assay. J. Pharmacobiodyn. 10 (1987) 431-435
29. Fujimoto K., Oka T., and Morimoto M. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Cancer Res. 47 (1987) 1516-1522
30. Inoue S., Kubota T., Ohishi T., Kuzuoka M., Oka S., Shimoyama Y., Kikuyama S., Ishibiki K., and Abe O. Antitumor activity of quinocarmycin citrate (KW-2152) against human tumor xenografts serially transplanted into nude mice. Keio J. Med. 37 (1988) 355-364
31. Inaba S., and Shimoyama M. Antitumor activity of quinocarmycin (KW2152) against various cultured leukemia and lymphoma cell lines in vitro. Cancer Res. 48 (1988) 6029-6032
32. Kanamaru R., Konishi Y., Ishioka C., Kakuta H., Sato T., Ishikawa A., Asamura M., and Wakui A. The mechanism of action of quinocarmycin citrate (KW 2152) on mouse L1210 cells in vitro. Cancer Chemother. Pharmacol. 22 (1988) 197-200
33. Saito H., Kobayashi S., Uosaki Y., Sato A., Fujimoto K., Miyoshi K., Ashizawa T., Morimoto M., and Hirata T. Synthesis and biological evaluation of quinocarcin derivatives. Chem. Pharm. Bull. (Tokyo) 38 (1990) 1278-1285
34. Saito H., Hirata T., Kasai M., Fujimoto K., Ashizawa T., Morimoto M., and Sato A. Synthesis and biological evaluation of quinocarcin derivatives: thioalkyl-substituted quinones and hydroquinones. J. Med. Chem. 34 (1991) 1959-1966
35. Plowman J., Dykes D.J., Narayanan V.L., Abbott B.J., Saito H., Hirata T., and Grever M.R. Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture and in mice. Cancer Res. 55 (1995) 862-867
36. Bunnell C.A., Supko J.G., Eder Jr. J.P., Clark J.W., Lynch T.J., Kufe D.W., and Shulman L.N. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother. Pharmacol. 48 (2001) 347-355
37. Scott J.D., and Williams R.M. Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. Chem. Rev. 102 (2002) 1669-1730
38. Hill G.C., Wunz T.P., and Remers W.A. Computer simulation of the binding of quinocarcin to DNA. Prediction of mode of action and absolute configuration. J. Comput. Aided Mol. Des. 2 (1988) 91-106
39. Flanagan M.E., Rollins S.B., and Williams R.M. Netropsin and spermine conjugates of a water-soluble quinocarcin analog: analysis of sequence-specific DNA interactions. Chem. Biol. 2 (1995) 147-156
40. Herberich B., Scott J.D., and Williams R.M. Synthesis of a netropsin conjugate of a water-soluble epi-quinocarcin analogue: the importance of stereochemistry at nitrogen. Bioorg. Med. Chem. 8 (2000) 523-532
41. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., and Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 (2002) 4316-4324
42. Tsukita S., Hieda Y., and Tsukita S. A new 82-kD barbed end-capping protein (radixin) localized in the cell-to-cell adherens junction: purification and characterization. J. Cell Biol. 108 (1989) 2369-2382
43. Bretscher A., Chambers D., Nguyen R., and Reczek D. ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu. Rev. Cell Dev. Biol. 16 (2000) 113-143
44. Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol. Cell. 92 (2000) 305-316
45. Bretscher A., Edwards K., and Fehon R.G. ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 3 (2002) 586-599
46. Hoeflich K.P., and Ikura M. Radixin: cytoskeletal adopter [sic] and signaling protein. Int. J. Biochem. Cell Biol. 36 (2004) 2131-2136
47. McClatchey A.I. Merlin and ERM proteins: unappreciated roles in cancer development?. Nat. Rev. Cancer 3 (2003) 877-883
48. Kouyama T., and Mihashi K. Fluorimetry study of N-(1-pyrenyl)iodoacetamide-labelled F-actin. Local structural change of actin protomer both on polymerization and on binding of heavy meromyosin. Eur. J. Biochem. 114 (1981) 33-38
49. Cooper J.A., Walker S.B., and Pollard T.D. Pyrene actin: documentation of the validity of a sensitive assay for actin polymerization. J. Muscle Res. Cell Motil. 4 (1983) 253-262
50. Henry M.D., Gonzalez Agosti C., and Solomon F. Molecular dissection of radixin: distinct and interdependent functions of the amino- and carboxy-terminal domains. J. Cell Biol. 129 (1995) 1007-1022
51. Vaiskunaite R., Adarichev V., Furthmayr H., Kozasa T., Gudkov A., and Voyno-Yasenetskaya T.A. Conformational activation of radixin by G13 protein α subunit. J. Biol. Chem. 275 (2000) 26206-26212
52. Roy C., Martin M., and Mangeat P. A dual involvement of the amino-terminal domain of ezrin in F- and G-actin binding. J. Biol. Chem. 272 (1997) 20088-20095
53. 2-terminal domain of ezrin correlates with its altered cellular distribution. J. Cell Biol. 151 (2000) 1067-1080
54. Hirao M., Sato N., Kondo T., Yonemura S., Monden M., Sasaki T., Takai Y., Tsukita S., and Tsukita S. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J. Cell Biol. 135 (1996) 37-51
55. Yonemura S., Hirao M., Doi Y., Takahashi N., Kondo T., Tsukita S., and Tsukita S. Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J. Cell Biol. 140 (1998) 885-895
56. 2-dependent cleavage of DNA by quinocarcin. J. Am. Chem. Soc. 114 (1992) 733-740
57. 2-dependent cleavage of DNA by tetrazomine. Biochemistry 33 (1994) 4086-4092
58. Williams R.M., Glinka T., Gallegos R., Ehrlich P.P., Flanagan M.E., Coffman H., and Park G. Synthesis, conformation, crystal structures and DNA cleavage abilities of tetracyclic analogs of quinocarcin. Tetrahedron 47 (1990) 2629-2642
59. McCormick F. Small-molecule inhibitors of cell signaling. Curr. Opin. Biotechnol. 11 (2000) 593-597
60. Way J.C. Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs. Curr. Opin. Chem. Biol. 4 (2000) 40-46
61. Cochran A.G. Protein-protein interfaces: mimics and inhibitors. Curr. Opin. Chem. Biol. 5 (2001) 654-659
62. Berg T. Modulation of protein-protein interactions with small organic molecules. Angew. Chem. Int. Ed. Engl. 42 (2003) 2462-2481
63. Gadek T.R., and Nicholas J.B. Small molecule antagonists of proteins. Biochem. Pharmacol. 65 (2003) 1-8
64. Sandrock T., and Kamb A. Non-traditional drug targets: high risk, high reward. Curr. Gene Ther. 3 (2003) 395-404
65. Arkin M.R., and Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3 (2004) 301-317
66. Pagliaro L., Felding J., Audouze K., Nielsen S.J., Terry R.B., Krog-Jensen C., and Butcher S. Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr. Opin. Chem. Biol. 8 (2004) 442-449
67. Arkin M. Protein-protein interactions and cancer: small molecules going in for the kill. Curr. Opin. Chem. Biol. 9 (2005) 317-324
68. Fry D.C., and Vassilev L.T. Targeting protein-protein interactions for cancer therapy. J. Mol. Med. 12 (2005) 955-963
69. Yin H., and Hamilton A.D. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem. Int. Ed. Engl. 44 (2005) 4130-4163
70. Zhao L., and Chmielewski J. Inhibiting protein-protein interactions using designed molecules. Curr. Opin. Struct. Biol. 15 (2005) 31-34
71. Isacke C.M., and Yarwood H. The hyaluronan receptor, CD44. Int. J. Biochem. Cell Biol. 34 (2002) 718-721
72. Jothy S. CD44 and its partners in metastasis. Clin. Exp. Metastasis 20 (2003) 195-201
73. Ponta H., Sherman L., and Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 4 (2003) 33-45
74. Marhaba R., and Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J. Mol. Histol. 35 (2004) 211-231
75. Spudich J.A., and Watt S. The regulation of rabbit skeletal muscle contraction. I. Biochemical studies of the interaction of the tropomyosin-troponin complex with actin and the proteolytic fragments of myosin. J. Biol. Chem. 246 (1971) 4866-4871
76. Pardee J.D., and Spudich J.A. Purification of muscle actin. Methods Enzymol. 85 pt B (1982) 164-181
77. Saito H., and Tadashi H. Synthetic approach to quinocarcin. Tetrahedron Lett. 28 (1987) 4065-4068
78. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
79. Funayama N., Nagafuchi A., Sato N., Tsukita S., and Tsukita S. Radixin is a novel member of the band 4.1 family. J. Cell Biol. 115 (1991) 1039-1048
80. Legg J.W., and Isacke C.M. Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, CD44. Curr. Biol. 8 (1998) 705-708
81. Reczek D., and Bretscher A. The carboxyl-terminal region of EBP50 binds to a site in the amino-terminal domain of ezrin that is masked in the dormant molecule. J. Biol. Chem. 273 (1998) 18452-18458
82. Lakshmikuttyamma A., Selvakumar P., Anderson D.H., Datla R.S., and Sharma R.K. Molecular cloning of bovine cardiac muscle heat-shock protein 70 kDa and its phosphorylation by cAMP-dependent protein kinase in vitro. Biochemistry 43 (2004) 13340-13347
83. Liberek K., Marszalek J., Ang D., Georgopoulos C., and Zylicz M. Escherichia coli DnaJ and GrpE heat shock proteins jointly stimulate ATPase activity of DnaK. Proc. Natl. Acad. Sci. USA 88 (1991) 2874-2878
84. Ziegelhoffer T., Lopez-Buesa P., and Craig E.A. The dissociation of ATP from hsp70 of Saccharomyces cerevisiae is stimulated by both Ydj1p and peptide substrates. J. Biol. Chem. 270 (1995) 10412-10419
85. Fewell S.W., Smith C.M., Lyon M.A., Dumitrescu T.P., Wipf P., Day B.W., and Brodsky J.L. Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity. J. Biol. Chem. 279 (2004) 51131-51140